Abstract
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Current Gene Therapy
Title: Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Volume: 11 Issue: 6
Author(s): Carolina Llanos, Leandro J. Carreno, Miguel A. Gutierrez, Claudia A. Riedel, Sergio H. Jacobelli and Alexis M. Kalergis
Affiliation:
Keywords: Autoimmune diseases, dendritic cells, immune tolerance, immunotherapy, lupus, T cells
Abstract: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by an excessive production of auto-antibodies against double-stranded DNA, nucleosomes, ribonucleoproteins and other nuclear components. Accumulation of self-reactive antibodies leads to immune complex deposition in blood vessels, activation of macrophages and complement, inflammation and subsequent tissue damage in several organs, such as the heart, kidneys, lungs and central nervous system. Although significant progress has been made in the past 30 years of research, no effective specific treatments are currently available. The course of this disease remains unpredictable and patients diagnosed with SLE face long-term treatments with the subsequent economic, social and health burden. From the immunological perspective, SLE is a genetic- and environment-controlled disease that involves almost every constituent of the immune system, including both innate and adaptive immunity. Therefore, several immune cell types and molecules could be susceptible for intervention and modulation to develop more effective and specific treatments. More importantly, such therapies are likely not to induce complete immunosuppression and show reduced side effects on patients. In this article we discuss recent work in the field of SLE pathogenesis with a focus on data that provide clues for therapy design and new treatments.
Export Options
About this article
Cite this article as:
Llanos Carolina, J. Carreno Leandro, A. Gutierrez Miguel, A. Riedel Claudia, H. Jacobelli Sergio and M. Kalergis Alexis, Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus, Current Gene Therapy 2011; 11 (6) . https://dx.doi.org/10.2174/156652311798192806
DOI https://dx.doi.org/10.2174/156652311798192806 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contribution of the Rho-kinase to Systemic Sclerosis and Behçet’s Disease
Current Pharmaceutical Design DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Autoimmunity and Apoptosis - Therapeutic Implications
Current Medicinal Chemistry Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Pharmacokinetic and Toxicological Characteristics of Tripterigium Glycosides and Their Derivatives
Current Drug Metabolism Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Interactions of Sex Steroids with Mechanisms of Inflammation
Current Drug Targets - Inflammation & Allergy Hepatic Manifestations in Juvenile Systemic Lupus Erythematosus
Recent Patents on Inflammation & Allergy Drug Discovery A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery Hot topic: Editorial [Therapeutic Potential of Peptide Motifs - Part IV] (Jean Claude Herve)
Current Pharmaceutical Design Pharmacological Modulation of Caspase Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Protein Engineering Studies for C-C Chemokine Receptor Type 2 (CCR2)
Current Enzyme Inhibition Molecular Mimicry in Autoimmune Neurological Disease after Viral Infection
Current Medicinal Chemistry Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued) Monoclonal Antibodies in the Treatment of Neuroimmunological Diseases
Current Pharmaceutical Design Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry Osteopontin; as a Target Molecule for the Treatment of Inflammatory Diseases
Current Drug Targets The Roles of MicroRNAs in Atherosclerosis
Current Medicinal Chemistry Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases
Current Pharmaceutical Design B Lymphocytes, Potent Antigen Presenting Cells for Preferential Expansion of Allo-Reactive FoxP3+ CD4 Regulatory T Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)